Targeted drug trial aims to shrink lung tumors before surgery
NCT ID NCT07156604
Summary
This study is testing whether a drug called Vebreltinib can shrink tumors in patients with a specific genetic type of non-small cell lung cancer before they have surgery. About 30 eligible patients will take the drug for 8 weeks prior to their planned operation. The main goal is to see how many patients have their tumors shrink significantly, which could make surgery more effective and potentially improve long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center, Shanghai,
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.